Cytovia is dedicated to the development of transformational cancer immunotherapies, addressing several of the most challenging unmet medical needs including the prevention of cancer relapse and metastasis. Cytovia focuses on Natural Killer (NK) cell biology and applies precision medicine tools to develop the right therapy for the right patient at the right stage of the disease. Cytovia has secured access to multiple advanced technologies, including allogeneic cell therapy, multispecific antibodies, and cytokines. Cytovia establishes development partnerships to accelerate time-to-market and commercialization alliances in order to optimize rapid adoption of its novel immunotherapies. 


Biotechnology

Cytovia Therapeutics

Daniel Teper

Wei Li, Ph.D

Michael Noonan

Wei Li

Armin Rath

The Research and Development team at Cytovia Therapeutics is dedicated to innovating and optimizing cancer immunotherapies, focusing on Natural Killer (NK) cell biology and precision medicine. Comprising experts in preclinical research and gene editing, the team conducts cutting-edge studies to develop novel therapeutic approaches aimed at preventing cancer relapse and metastasis. By leveraging advanced technologies and strategic partnerships, the team drives the discovery and development of targeted treatments for patients at various disease stages.

Research and Development

Advisory Board

Leadership Team

Research and Development

About

Team members

Other teams at Cytovia Therapeutics

Advisory Board

Leadership Team